# Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer

> **NCT06225622** · PHASE1 · UNKNOWN · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 78 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Irinotecan Liposome
- **DRUG:** Oxaliplatin
- **DRUG:** 5-FU
- **DRUG:** LV
- **DRUG:** Bevacizumab
- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT06225622
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-03-11
- **Primary completion:** 2026-01-01
- **Final completion:** 2026-05-01
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2024-03-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06225622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06225622, "Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06225622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*